Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LiteLabel is a biotechnology company specializing in the development of site-specific labeling technologies for biomolecules, particularly for use in radiopharmaceuticals. The company's platform enables the precise attachment of radioactive isotopes or other payloads to antibodies and peptides, ensuring optimal pharmacokinetics and binding affinity. By providing a standardized and efficient labeling process, LiteLabel aims to accelerate the development of targeted diagnostic imaging agents and radioligand therapies. The technology is particularly relevant for PET and SPECT imaging in oncology and other therapeutic areas requiring high-precision molecular targeting. Spun out from the Radboud University Medical Center, LiteLabel addresses the limitations of traditional random labeling methods which can impair the biological activity of targeting vectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lite Label.